UPDATE: Targacept Official Release Confirms Phase 2b Trial in TC-1734 Did Not Show Superiority to Donepezil
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics™, today announced top-line results from a
Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to
moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective
of showing superiority to donepezil, the marketed medication most often
prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did
not include a placebo arm and was not designed to determine whether TC-1734 is
equivalent to donepezil. The co-primary endpoints for the study were measures
of cognitive function and global function. Consistent with previous clinical
results, TC-1734 exhibited a benign safety and tolerability profile.
“We are disappointed for Alzheimer's disease patients and their families. We
designed a rigorous study to provide a definitive answer on whether TC-1734
could be a better treatment option than the current standard of care in what
has been a very difficult disease area for the development of novel
therapeutics. Based on these results, we do not intend to invest in further
development of TC-1734,” said Dr. Stephen A. Hill, Targacept's President and
Chief Executive Officer. “I want to thank the investigators, patients and my
colleagues at Targacept for their efforts.”
Analyses of the full dataset from the trial are ongoing and Targacept plans to
present and publish more detailed results over the coming months.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.